Analysis of 24 cases of cryptococcal meningitis treated with fluconazole
10.3760/cma.j.issn.1000-6680.2009.06.009
- VernacularTitle:氟康唑治疗隐球菌脑膜炎24例临床分析
- Author:
Xueting OU
;
Changming GENG
;
Bin XU
;
Jiqin WU
;
Xinyu WANG
;
Shu CHEN
;
Feifei YANG
;
Wanqin ZHANG
;
Liping ZHU
;
Xinhua WENG
- Publication Type:Journal Article
- Keywords:
Meningitis,cryptococcal,Acquired immunodeficiency syndrome;
Fluconazole;
Flucytosine;
Follow-up studies
- From:
Chinese Journal of Infectious Diseases
2009;27(6):357-359
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate clinical features,therapeutic effects and outcomes of patients with non-human immunodeficiency virus(HIV)-infected cryptococcal meningitis treated with fluconazole or fluconazole and flucytosine.Methods Twenty-four cases of non-HIV-infected cryptococcal meningitis(fluconazole with or without flucytosine as initial therapy)in Huashan Hospital,Fudan University from 1997 to 2007 were retrospectively reviewed.Clinical manifestations,therapeutic effects and outcomes of the patients were collected.Results Fluconazole was administered with median dosage of 400 mg/d,for a median duration of 20.5 days.After fluconazole initial therapy for 2 weeks,16.7% showed partial response,83.3% showed no response,and the overall response rate was 16.7%.After 10 weeks,33.3% showed partial response,29.2% showed complete response,16.7% showed no response,and the overall response rate was 62.5%.Mortality at week 10 was 20.8%.Twenty-two patients who failed to respond to initial therapy were switched to other antifungal drugs(amphotericin B,amphotericin B colloidal dispersion,itraconazole)or other fluconazole containing combined therapy.Eleven out of the 24 patients died during one-year follow-up,8 of whom died of eryptococcal meningitis,and 3 died of other diseases.Conclusions The initial therapy of fluconazole with or without flucytosine is inefficient,and most of the patients need other antifungal drugs because of initial therapy failure.Therefore,fluconazole might not be appropriate for initial therapy in non-HIV-infected cryptococcal meningitis.
